Genocea shelves its lead drug, slashes staff and switches focus to trendy neoantigens
Neoantigens are a hot commodity right now in the sizzling immuno-oncology field, and that looks too attractive for Genocea to pass up on.
The biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
